Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression-Reference-Cited by-同舟云学术

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

Published:2012-09 Issue:9 Volume:20 Page:1689-1698
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Perez Omar D,Logg Christopher R,Hiraoka Kei,Diago Oscar,Burnett Ryan,Inagaki Akihito,Jolson Dawn,Amundson Karin,Buckley Taylor,Lohse Dan,Lin Amy,Burrascano Cindy,Ibanez Carlos,Kasahara Noriyuki,Gruber Harry E,Jolly Douglas J

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference37 articles.

1. History of oncolytic viruses: genesis to genetic engineering;Kelly;Mol Ther,2007

2. Novel oncolytic viruses: riding high on the next wave;Stanford;Cytokine Growth Factor Rev,2010

3. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity;Barral;Pharmacol Ther,2009

4. Diplomatic immunity: turning a foe into an ally;Parato;Curr Opin Mol Ther,2009

5. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways;Naik;Expert Opin Biol Ther,2009

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification;Molecular Therapy: Oncology;2024-09

2. Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma;Neuro-Oncology;2024-08-08

3. Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model;Cancer Gene Therapy;2024-07-23

4. IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma;2024-04-03

5. Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives;Cancers;2024-03-25